Oxygen Biotherapeutics, Inc. (OXBO) Announces Key Details Of Phase 3 Trial Protocol For Levosimendan  
1/6/2014 9:47:46 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (“OBI”) (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the protocol of their phase 3 trial for levosimendan has been published on, “Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Heart Surgery on Cardiopulmonary Bypass.”

Help employers find you! Check out all the jobs and post your resume.